Compare Vanguard Dividend Appreciation Index Fund ETF (VIG) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard Dividend Appreciation Index Fund ETF vs State Street SPDR S&P Biotech ETF — how do they compare? Vanguard Dividend Appreciation Index Fund ETF trades at $238.66 (market cap $132.40B), while State Street SPDR S&P Biotech ETF trades at $154.07 (market cap $10.11B). The key difference: Vanguard Dividend Appreciation Index Fund ETF is far larger — about 13.1× State Street SPDR S&P Biotech ETF's market cap, and State Street SPDR S&P Biotech ETF is more actively traded (12,903,266 versus 1,287,188). Which is the better fit depends on your goals — on Pluang, investors hold Vanguard Dividend Appreciation Index Fund ETF for 133 Days and State Street SPDR S&P Biotech ETF for 37 Days on average.
| VIG | XBI | |
|---|---|---|
Market Cap | $132.40B | $10.11B |
Volume | 1,287,188 | 12,903,266 |
52-Week High | $246.61 | $169.55 |
52-Week Low | $210.70 | $104.99 |
Typical Hold Time | 133 Days | 37 Days |
Sector | — | Broad Market / Factor |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
VIG trades at $237.99, up 0.42% with a bullish technical signal from moving averages. The ETF focuses on dividend growth companies with 10+ years of consecutive dividend increases, offering a lower yield but stronger growth profile compared to peers. Recent news highlights its 7.5% quarterly dividend increase and long-term return potential averaging 10% annually since inception.
Outlook remains positive for investors seeking dividend growth with moderate risk, though the low current yield and exclusion of high-yield stocks present trade-offs. Key risks include market volatility and the ETF's specific eligibility rules limiting certain holdings. The growth-oriented strategy appeals to long-term investors prioritizing increasing income over current yield.
XBI trades at $153.34, up 2.07% today, but faces bearish technical signals with 17 sell indicators versus 4 buys. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from recent M&A activity and positive clinical trial catalysts. Current price sits near resistance at $154, with support at $147.
Biotech sector optimism is growing with cancer vaccine breakthroughs and improved capital access, though XBI's 0.35% expense ratio is higher than broader healthcare ETFs. Key risks include sector volatility and regulatory uncertainty, while analyst consensus remains neutral with 100% hold rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vanguard Dividend Appreciation Index Fund ETF
The advisor employs an indexing investment approach designed to track the performance of the index, which consists of common stocks of companies that have a record of increasing dividends over time. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VIG →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
